A5043771424- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- COVID-19 and healthcare impacts
- Renal cell carcinoma treatment
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Cancer, Lipids, and Metabolism
- Immunotherapy and Immune Responses
- Bioinformatics and Genomic Networks
- Cancer Mechanisms and Therapy
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Chemotherapy-related skin toxicity
- Cancer Research and Treatments
- COVID-19 Clinical Research Studies
- Cutaneous Melanoma Detection and Management
- Atrial Fibrillation Management and Outcomes
- Gastric Cancer Management and Outcomes
- Ferroptosis and cancer prognosis
- Computational Drug Discovery Methods
- Lung Cancer Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
Sechenov University
2018-2025
Ministry of Health of the Russian Federation
2023
Moscow Institute of Physics and Technology
2023
Russian Scientific Center of Surgery
2015-2017
Treatment options are limited for patients with previously treated metastatic colorectal cancer (mCRC). In the LEAP-017 study, we evaluate whether lenvatinib in combination pembrolizumab improves outcomes compared standard of care (SOC) mismatch repair proficient or not microsatellite instability high (pMMR MSI-H) mCRC.
OncoboxPD (Oncobox pathway databank) available at https://open.oncobox.com is the collection of 51 672 uniformly processed human molecular pathways. Superposition all pathways formed interactome graph protein-protein interactions and metabolic reactions containing 361 654 64 095 participants. Pathways are classified by biological processes, each node algorithmically functionally annotated specific activator/repressor role. This enables online calculation statistically supported activation...
Gastric cancer (GC) is the fifth-ranked type by associated mortality. The proportion of early diagnosis low, and most patients are diagnosed at advanced stages. First-line therapy standardly includes fluoropyrimidines platinum compounds with trastuzumab for HER2-positive cases. For recurrent disease, there several alternative options including ramucirumab, a monoclonal therapeutic antibody that inhibits VEGF-mediated tumor angiogenesis binding VEGFR2, alone or in combination other drugs....
Normal tissues are essential for studying disease-specific differential gene expression. However, healthy human controls typically available only in postmortal/autopsy settings. In cancer research, fragments of pathologically normal tissue adjacent to tumor site frequently used as the controls. it is largely underexplored how cancers can systematically influence expression neighboring tissues. Here we performed a comprehensive pan-cancer comparison molecular profiles solid tumor-adjacent and...
Cholangiocarcinoma is an aggressive tumor with poor prognosis. Most of the cases are not available for surgery at stage diagnosis and best clinical practice chemotherapy results in about 12-month median survival. Several tyrosine kinase inhibitors (TKIs) currently under investigation as alternative treatment option cholangiocarcinoma. Thus, report personalized selection effective inhibitor case outcome interest. Here we a metastatic cholangiocarcinoma (MCC) 72-year-old man, sequentially...
Individual gene expression and molecular pathway activation profiles were shown to be effective biomarkers in many cancers. Here, we used the human interactome model algorithmically build 7470 pathways centered around individual products. We assessed their associations with tumor type survival comparison previous generation of (3022 "classical" pathways) RNA transcripts or proteomic genes, for 8141 1117 samples, respectively. For all analytes data, respectively, found a total 7441 7343...
Background CV8102, a toll-like receptor 7/8 and RIG I agonist, has demonstrated antitumor immune responses in preclinical studies. We investigated intratumoral (IT) administration of CV8102 patients with anti-programmed cell death protein-1 (PD-1) therapy-naïve or anti-PD-1 therapy-refractory cutaneous melanoma (cMEL) advanced squamous carcinoma, head neck carcinoma adenoid cystic carcinoma. Methods This open-label, cohort-based, phase dose escalation study aimed to establish the maximum...
Ovarian cancer is the fifth leading cause of cancer-related female mortality and most lethal gynecological cancer. In this report, we present a rare case recurrent granulosa cell tumor (GCT) ovary. We describe 26-yr-old woman with progressive GCT right ovary despite multiple lines therapy who underwent salvage selection based on novel bioinformatical decision support tool (Oncobox). This analysis generated list potentially actionable compounds, which when used clinically lead to partial...
Aim: To provide a breast cancer (BC) methylotype classification by genome-wide CpG islands bisulfite DNA sequencing. Materials & methods: XmaI-reduced representation sequencing methylation method was used to profile of 110 BC samples and 6 normal samples. Intrinsic subtypes were elicited unsupervised hierarchical cluster analysis, cluster-specific differentially methylated genes identified. Results conclusion: Overall, six distinct methylotypes cell lines constitute separate group extremely...
Abstract Background: Overall survival of advanced colorectal cancer (CRC) patients remains poor, and gene expression analysis could potentially complement detection clinically relevant mutations to personalize CRC treatments. Methods: We performed RNA sequencing formalin-fixed, paraffin-embedded (FFPE) tissue samples 23 interpreted the data obtained using bioinformatic method Oncobox for expression-based rating targeted therapeutics. ranks drugs according efficiency score calculated target...
Regardless of the presence or absence specific diagnostic mutations, many cancer patients fail to respond EGFR-targeted therapeutics, and a personalized approach is needed identify putative (non)responders. We found previously that human peripheral blood EGF can modulate activities EGFR-specific drugs on inhibiting clonogenity in model EGFR-positive A431 squamous carcinoma cells. Here, we report serum dramatically abolish cell growth rate inhibition by cetuximab erlotinib. show this...
Non-small cell lung carcinoma (NSCLC) is the major cause of cancer-associated mortality. Identification rearrangements in anaplastic lymphoma kinase (ALK) gene an effective instrument for more targeted therapy NSCLC using ALK inhibitors dramatically raising progression-free survival ALK-mutated group patients. However, tumors frequently develop resistance to inhibitors. We describe here a case 48 y.o. male patient with ALK-positive who was clinically managed 6.5 years from diagnosis. The...